Most people hit early with coronavirus lost their smell. Now, not so much. Scientists are starting to figure out why and what that means.
Author: Karen Weintraub, USA TODAY
Effective treatments for COVID are now available. Why are they not being used?
Awareness varies about the availability and effectiveness of ‘miracle’ COVID treatments, experts say. Once in short supply, they are now underused.
Moderna’s combination COVID booster appears more protective against variants, company study finds
Concerned that the original vaccine may lose protectiveness as the SARS-CoV-2 virus evolves, companies have been testing different vaccine versions.
Why do some people seem unable to catch COVID? Scientists are looking for answers.
Scientists are studying people intentionally exposed to the virus that causes COVID and those who don’t get sick to find out why some avoid infection.
Federal agencies authorize second COVID-19 booster shot for Americans 50 and older
A second booster shot of the Pfizer or Moderna COVID-19 vaccine is allowed for those 50 and up. Immunocompromised can now get a fifth shot.
Delay in COVID vaccines for kids upset parents. Experts say it was the right thing to do.
The FDA won’t have enough data until the spring to judge whether a vaccine is safe and effective for young children, experts tell USA TODAY.
Just how bad is it to be in ICU with COVID? Far more miserable than people realize, experts say
Weeks of sedation, months of rehab and perhaps years of lingering symptoms is typical for people who have ended up in an ICU because of COVID.
Monoclonal antibodies were ‘doing nothing’ against omicron. That’s why FDA pulled its authorization.
Monoclonal antibodies from drug-makers Regeneron and Eli Lilly have proven ineffective against the omicron variant of COVID-19.
Omicron’s new variant cousin, BA.2, has arrived in the US. But don’t panic yet, experts say.
Cases of omicron BA.2 have been reported in at least four states – California, New Mexico, Texas and Washington – and on three other continents.
Pfizer and BioNTech announce plans to test omicron-specific COVID-19 vaccine in adult trials
Pfizer and BioNTech will conduct three simultaneous trials in adults to determine if an omicron-specific vaccine is more effective than current shots.